title: [Clinical study on chemotherapy for multiple myeloma: Part IV: Prognostic factors related to long survival].
authors.forename: T
authors.initials: T
authors.lastname: Adachi
authors.forename: T
authors.initials: T
authors.lastname: Sezaki
authors.forename: T
authors.initials: T
authors.lastname: Hoshijima
authors.forename: K
authors.initials: K
authors.lastname: Izumi
authors.forename: T
authors.initials: T
authors.lastname: Tsubota
authors.forename: K
authors.initials: K
authors.lastname: Asano
authors.forename: I
authors.initials: I
authors.lastname: Takahashi
authors.forename: I
authors.initials: I
authors.lastname: Kimura
authors.forename: M
authors.initials: M
authors.lastname: Murakami
mesh_terms: D015250:Aclarubicin; D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D009279:Naphthacenes / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011379:Prognosis; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D009279:Naphthacenes; D009607:Nitrosourea Compounds; D011344:Procarbazine; D014750:Vincristine; D015250:Aclarubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D007069:Ifosfamide